Schonfeld Strategic Advisors LLC Acquires 1,382,176 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Schonfeld Strategic Advisors LLC lifted its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,789,379 shares of the company's stock after acquiring an additional 1,382,176 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 4.48% of Verve Therapeutics worth $21,372,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of VERV. Barclays PLC increased its stake in shares of Verve Therapeutics by 139.8% in the third quarter. Barclays PLC now owns 222,919 shares of the company's stock valued at $1,079,000 after buying an additional 129,944 shares in the last quarter. Geode Capital Management LLC grew its holdings in Verve Therapeutics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company's stock worth $7,749,000 after acquiring an additional 40,915 shares during the last quarter. Franklin Resources Inc. increased its position in Verve Therapeutics by 20.9% in the 3rd quarter. Franklin Resources Inc. now owns 34,155 shares of the company's stock valued at $172,000 after acquiring an additional 5,914 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after acquiring an additional 3,964 shares during the last quarter. Finally, Green Alpha Advisors LLC lifted its position in shares of Verve Therapeutics by 15.0% during the fourth quarter. Green Alpha Advisors LLC now owns 29,438 shares of the company's stock worth $166,000 after purchasing an additional 3,840 shares in the last quarter. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Trading Down 5.6 %

Shares of NASDAQ:VERV traded down $0.31 during midday trading on Friday, hitting $5.19. The company had a trading volume of 2,918,009 shares, compared to its average volume of 1,788,886. Verve Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $9.31. The firm has a fifty day simple moving average of $5.16 and a 200 day simple moving average of $5.95. The stock has a market cap of $462.65 million, a price-to-earnings ratio of -2.11 and a beta of 1.86.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on VERV. HC Wainwright boosted their price objective on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Canaccord Genuity Group boosted their target price on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Guggenheim upped their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Finally, Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 4th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.